Receptor, Fibroblast Growth Factor, Type 1, antagonists & inhibitors

All categories

DBCAT002791Pharmacologic class

A DrugBank category of 2 drugs. 2 of them are approved.

Drugs: Infigratinib
Pemigatinib

What you can answer from here — as of October 24, 2016

2DrugsEach linked to its full drug card

Listed above

5Drug targetsEvery drug–target pair in the class, with bond type

26Marketed productsAcross the regions we cover, with dosage forms and routes

1Route of administrationHow the drugs in this class are given

Which targets do Receptor, Fibroblast Growth Factor, Type 1, antagonists & inhibitors share, and which companies have late-stage candidates in this class?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account